{"id":36266,"date":"2019-09-26T09:00:00","date_gmt":"2019-09-26T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/"},"modified":"2019-09-26T09:00:00","modified_gmt":"2019-09-26T07:00:00","slug":"ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/","title":{"rendered":"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019"},"content":{"rendered":"<p><b>Ces pr\u00e9sentations font \u00e9tat des avanc\u00e9es prometteuses dans le traitement du carcinome h\u00e9patocellulaire avanc\u00e9, du cancer du pancr\u00e9as m\u00e9tastatique et des tumeurs neuroendocrines.<\/b><\/p>\n<p><b>Paris (France), 26\u00a0septembre 2019<\/b>\u00a0\u2013 Ipsen (Euronext\u00a0: IPN\u00a0; ADR\u00a0: IPSEY) a annonc\u00e9 aujourd\u2019hui que des essais cliniques sur le cabozantinib (Cabometyx\u00ae) dans le traitement de divers types de tumeurs feront l\u2019objet de quatre pr\u00e9sentations lors du Congr\u00e8s 2019 de l\u2019<em>European Society for Medical Oncology\u00a0<\/em>(ESMO) qui se tiendra du 27\u00a0septembre au 1er octobre \u00e0 Barcelone, en Espagne.<\/p>\n<p>\u00ab\u00a0La mission d\u2019Ipsen est d\u2019acc\u00e9l\u00e9rer la d\u00e9couverte, le d\u00e9veloppement et la commercialisation de nouveaux m\u00e9dicaments. Nous sommes ravis de communiquer les donn\u00e9es de ces nouvelles \u00e9tudes lors de l\u2019ESMO et de pr\u00e9senter les avanc\u00e9es potentielles dans le traitement de certains cancers pour lesquels les options th\u00e9rapeutiques sont limit\u00e9es afin de ne n\u00e9gliger aucun patient\u00a0\u00bb, a d\u00e9clar\u00e9 le Dr Alexandre Lebeaut, Vice-Pr\u00e9sident Ex\u00e9cutif, R&amp;D et Chief Scientific Officer d\u2019Ipsen.<\/p>\n<p>Principales \u00e9tudes sur des m\u00e9dicaments d\u2019Ipsen pr\u00e9sent\u00e9s lors de l\u2019ESMO 2019\u00a0:<\/p>\n<ul>\n<li style=\"margin-bottom:3px\"><b>Aper\u00e7u\u00a0<\/b>de l\u2019\u00e9tude pivotale de phase III (COSMIC-312) sur le cabozantinib (C) en combinaison avec l\u2019at\u00e9zolizumab versus soraf\u00e9nib chez des patients atteints de carcinome h\u00e9patocellulaire avanc\u00e9 (CHCa) n\u2019ayant pas re\u00e7u de traitement anticanc\u00e9reux syst\u00e9mique ant\u00e9rieur<\/li>\n<li style=\"margin-bottom:3px\"><b>Nouvelle analyse QTWiST\u00a0<\/b>de l\u2019\u00e9tude de phase III CELESTIAL sur l\u2019effet du cabozantinib en traitement de deuxi\u00e8me ligne sur l\u2019\u00e9tat de sant\u00e9 de patients atteints de CHCa post-soraf\u00e9nib<\/li>\n<\/ul>\n<p>\u00ab\u00a0Nous observons des avanc\u00e9es dans les programmes de recherche sur les cancers difficiles \u00e0 traiter, comme le cancer du poumon \u00e0 petites cellules et l\u2019ad\u00e9nocarcinome pancr\u00e9atique. Parall\u00e8lement, nous nouons des partenariats pour catalyser et amplifier nos efforts afin d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement de nouvelles strat\u00e9gies de traitement pour les patients dont les besoins m\u00e9dicaux sont importants\u00a0\u00bb, a d\u00e9clar\u00e9 Bartek Bednarz, Senior Vice-President, Franchise Oncologie d\u2019Ipsen. \u00ab\u00a0Le Congr\u00e8s 2019 de l\u2019ESMO marque un tournant de notre partenariat avec Exelixis pour le d\u00e9veloppement du cabozantinib (Cabometyx\u00ae). En effet, nous avons d\u00e9pass\u00e9 100 abstracts communs sur le cabozantinib accept\u00e9s dans divers congr\u00e8s m\u00e9dicaux, leur pr\u00e9sentation mettant en \u00e9vidence notre vision commune en mati\u00e8re de traitement des cancers difficiles \u00e0 traiter.\u00a0\u00bb<br \/>Suivez Ipsen sur Twitter via\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-znurcZWvrtCdLxzcjyFZXH7MK6HGH00avyEPBzgXxug-ZxwqaYn3REBlGOJYebCWINSb8YELi087GkF_O7Vd6AycYx51QFJ4exQdsZ3Wl8=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>@IpsenGroup<\/b><\/a>\u00a0et tenez-vous au courant des informations et actualit\u00e9s de l\u2019ESMO 2019 en utilisant le hashtag #ESMO19.<\/p>\n<p><b>Aper\u00e7u des principales pr\u00e9sentations concernant des m\u00e9dicaments Ipsen en d\u00e9veloppement lors du Congr\u00e8s 2019 de l\u2019ESMO\u00a0:<\/b><\/p>\n<table style=\"border-collapse: collapse;width:731px;border-collapse:collapse\">\n<tr>\n<td><b>M\u00e9dicament<\/b><\/td>\n<td><b>Titre de l\u2019abstract<\/b><\/td>\n<td><b>Num\u00e9ro\/heure de l\u2019abstract (CEST)<\/b><\/td>\n<\/tr>\n<tr>\n<td rowspan=\"4\">Cabometyx\u00ae<br \/>(cabozantinib)<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/td>\n<td>Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study<\/td>\n<td>Abstract 754P \u2013 Pr\u00e9sentation de poster \u2013 Dimanche 29\u00a0septembre, 12h00\u00a0; Hall 4<\/td>\n<\/tr>\n<tr>\n<td>Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)<\/td>\n<td>Abstract 678PD \u2013 Discussion de poster \u2013 Cat\u00e9gorie\u00a0: Tumeurs gastrointestinales, non colorectales\u00a0; Discussion de poster \u2013 Samedi 28\u00a0septembre, 17h10\u00a0; Hall 7<\/td>\n<\/tr>\n<tr>\n<td>Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)<\/td>\n<td>Abstract 749P \u2013 Pr\u00e9sentation de poster \u2013 Dimanche 29\u00a0septembre, 12h00\u00a0; Hall 4<\/td>\n<\/tr>\n<tr>\n<td>Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab vs sorafenib in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received prior systemic anticancer therapy<\/td>\n<td>Abstract 833TiP \u2013 Pr\u00e9sentation de poster \u2013 Dimanche 29\u00a0septembre, 12h00\u00a0; Hall 4<\/td>\n<\/tr>\n<tr>\n<td>Onivyde\u00ae\u00a0(injection d\u2019irinot\u00e9can liposomal) (nal-IRI\/irinot\u00e9can liposomal)<\/td>\n<td>Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)<\/td>\n<td>Abstract 691P \u2013 Pr\u00e9sentation de poster \u2013 Dimanche 29\u00a0septembre, 12h00\u00a0; Hall 4<\/td>\n<\/tr>\n<tr>\n<td>Somatuline\u00ae\u00a0Autogel\u00ae\u00a0(lanr\u00e9otide autogel\/depot)<\/td>\n<td>Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen<\/td>\n<td>Abstract 1388P \u2013 Pr\u00e9sentation de poster \u2013 Dimanche 29\u00a0septembre, 12h00\u00a0; Hall 4<\/td>\n<\/tr>\n<\/table>\n<p><b>Principale pr\u00e9sentation d\u2019\u00e9tude parrain\u00e9e par l\u2019investigateur concernant un m\u00e9dicament Ipsen en d\u00e9veloppement lors du Congr\u00e8s 2019 de l\u2019ESMO\u00a0:<\/b><\/p>\n<table style=\"border-collapse: collapse;width:731px;border-collapse:collapse\">\n<tr>\n<td><b>M\u00e9dicament<\/b><\/td>\n<td><b>Titre de l\u2019abstract<\/b><\/td>\n<td><b>Num\u00e9ro\/heure de l\u2019abstract (CEST)<\/b><\/td>\n<\/tr>\n<tr>\n<td>Onivyde\u00ae\u00a0(injection d\u2019irinot\u00e9can liposomal) (nal-IRI\/irinot\u00e9can liposomal)<\/td>\n<td>Multicenter randomized phase II trial of 5-Fluorouracil\/leucovorin (5-FU\/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial<\/td>\n<td>Abstract 829TiP \u2013 Pr\u00e9sentation de poster \u2013 Dimanche 29\u00a0septembre, 12h00\u00a0; Hall 4<\/td>\n<\/tr>\n<\/table>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Pi\u00e8ce jointe<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=cdiYe_McJkpg1nxA0_2ztzsN5xcet83fpEPaGSx_dtglpZFdRUe3yR9qGJFZyByatZkadrPIU8VmyogcEq85W4_NcCJzDzwoYHyRXD69uImFyZcW6kP5zeyG47-wV2zs7vhmkR7qBbCuoJ5k549F7KLE1wFLtomRpj-j6osV9bj9IKrdGmwKMhGwOG8js2NZHBMD1VrVPa4AGeKS9R9fwg==\" title=\"Ipsen-Oncology-ESMO-curtain-raiser_FINAL_FR-1\" rel=\"nofollow noopener\">Ipsen-Oncology-ESMO-curtain-raiser_FINAL_FR-1<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[3556,3560],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019\",\"datePublished\":\"2019-09-26T07:00:00+00:00\",\"dateModified\":\"2019-09-26T07:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/\"},\"wordCount\":809,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Corporate\",\"Oncologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/\",\"name\":\"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2019-09-26T07:00:00+00:00\",\"dateModified\":\"2019-09-26T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/","og_site_name":"Global","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019","datePublished":"2019-09-26T07:00:00+00:00","dateModified":"2019-09-26T07:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/"},"wordCount":809,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Corporate","Oncologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/","name":"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2019-09-26T07:00:00+00:00","dateModified":"2019-09-26T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGJjZDcwNTctNzdhMS00ZWE3LTk5MTgtMGQ5ZDFmYjllZDQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presentera-des-etudes-qui-mettent-en-valeur-de-nouvelles-strategies-pour-les-cancers-difficiles-a-traiter-lors-du-congres-de-lesmo-2019\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Ipsen pr\u00e9sentera des \u00e9tudes qui mettent en valeur de nouvelles strat\u00e9gies pour les cancers difficiles \u00e0 traiter lors du Congr\u00e8s de l\u2019ESMO 2019"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36266"}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36266\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}